A-Alpha Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $22.4M

  • Investors
  • 18

A-Alpha Bio General Information

Description

Developer of synthetic biotechnology and machine learning designed to accelerate drug development with synthetic biology and next-generation sequencing. The company's biotechnology measures interactions between biologics libraries and multiple targets in a single experimental step that reduces time spent and cost while improving success rates, enabling researchers to discover, optimize, and characterize drugs in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2101 4th Avenue
  • Suite 500
  • Seattle, WA 98121
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 2101 4th Avenue
  • Suite 500
  • Seattle, WA 98121
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

A-Alpha Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A2) 25-Jul-2023 $22.4M Completed Pre-Clinical Trials
8. Early Stage VC (Series A) 08-Sep-2021 Completed Pre-Clinical Trials
7. Grant 09-Jul-2020 Completed Pre-Clinical Trials
6. Seed Round 13-Sep-2019 Completed Pre-Clinical Trials
5. Grant 30-May-2019 Completed Pre-Clinical Trials
4. Grant 01-Jul-2018 Completed Pre-Clinical Trials
3. Accelerator/Incubator 25-Jul-2017 Completed Startup
2. Grant 25-May-2017 $52.5K Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view A-Alpha Bio’s complete valuation and funding history, request access »

A-Alpha Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
Seed-1 187,549 $0.000100 6% $2.63 $2.63 1x $2.63 1.93%
Seed 930,620 $0.000100 6% $2.63 $2.63 1x $2.63 9.58%
To view A-Alpha Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

A-Alpha Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of synthetic biotechnology and machine learning designed to accelerate drug development with synthetic biology
Drug Discovery
Seattle, WA
35 As of 2026

San Diego, CA
 

San Mateo, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

A-Alpha Bio Competitors (33)

One of A-Alpha Bio’s 33 competitors is Vividion Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vividion Therapeutics Formerly VC-backed San Diego, CA
BigHat Biosciences Venture Capital-Backed San Mateo, CA
Onyx Venture Capital-Backed Berkeley, CA
Arvinas Formerly VC-backed New Haven, CT
Integral Molecular Private Debt Financed Philadelphia, PA
You’re viewing 5 of 33 competitors. Get the full list »

A-Alpha Bio Patents

A-Alpha Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250372208-A1 Synthetic augmentation of multiple sequence alignment of protein-protein interactions Pending 31-May-2024
WO-2025251028-A1 Synthetic augmentation of multiple sequence alignment of protein-protein interactions Pending 31-May-2024
US-12281147-B2 Interleukin 21 variants Active 14-Aug-2023
US-20250059247-A1 Interleukin 21 variants Active 14-Aug-2023
WO-2025038726-A2 Interleukin 21 variants Inactive 14-Aug-2023 C07K14/54
To view A-Alpha Bio’s complete patent history, request access »

A-Alpha Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

A-Alpha Bio Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Breakout Ventures Venture Capital Minority
Lux Capital Venture Capital Minority
Perceptive Advisors Venture Capital Minority
Xontogeny Accelerator/Incubator Minority
AME Cloud Ventures Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

A-Alpha Bio FAQs

  • When was A-Alpha Bio founded?

    A-Alpha Bio was founded in 2017.

  • Where is A-Alpha Bio headquartered?

    A-Alpha Bio is headquartered in Seattle, WA.

  • What is the size of A-Alpha Bio?

    A-Alpha Bio has 35 total employees.

  • What industry is A-Alpha Bio in?

    A-Alpha Bio’s primary industry is Drug Discovery.

  • Is A-Alpha Bio a private or public company?

    A-Alpha Bio is a Private company.

  • What is the current valuation of A-Alpha Bio?

    The current valuation of A-Alpha Bio is .

  • What is A-Alpha Bio’s current revenue?

    The current revenue for A-Alpha Bio is .

  • How much funding has A-Alpha Bio raised over time?

    A-Alpha Bio has raised $45.6M.

  • Who are A-Alpha Bio’s investors?

    Breakout Ventures, Lux Capital, Perceptive Advisors, Xontogeny, and AME Cloud Ventures are 5 of 18 investors who have invested in A-Alpha Bio.

  • Who are A-Alpha Bio’s competitors?

    Vividion Therapeutics, BigHat Biosciences, Onyx, Arvinas, and Integral Molecular are some of the 33 competitors of A-Alpha Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process